Abstract PGE, and PGE2 are potent stimulators of bone formation. Osteogenesis is strongly dependent on angiogenesis. Vascular endothelial growth factor (VEGF), a secreted endothelial cellspecific mitogen, has been implicated in physiological and pathological angiogenesis. The aim of this study was to examine the possible role of VEGF in PG stimulation of bone formation. We found that in rat calvaria-derived osteoblast-enriched cells and in the osteoblastic RCT-3 cell line PGE2 and El increased VEGF mRNA and protein levels. The increased expression of VEGF mRNA produced by PGE2 was rapid (maximal at 1 h), transient (declined by 3 h), potentiated by cycloheximide, and abolished by actinomycin D. PGE2 had no effect on VEGF mRNA stability, suggesting transcriptional regulation ofVEGF expression by PGE2. Rp-cAMP, a cAMP antagonist, suppressed VEGF mRNA induced by PGE2, indicating cAMP mediation. The upregulation of VEGF expression by PGE2 in the preosteoblastic RCT-1 cells was potentiated by treatment with retinoic acid, which induces the differentiation of these cells. The upregulation of VEGF mRNA by PGE2 was inhibited by dexamethasone treatment. In addition, Northern blot analysis showed that VEGF mRNA is expressed in adult rat tibia. In summary, we documented, for the first time, the expression of VEGF in osteoblasts and in bone tissue. Stimulation of VEGF expression by PGs and its suppression by glucocorticoids, which, respectively, stimulate and suppress bone formation, strongly implicate the involvement of VEGF in bone metabolism. (J. Clin. Invest. 1994.93:2490-2496
Introduction
Angiogenesis, the development of a microvascular network for blood supply, is critical for the development, remodeling, and healing (1, 2) of most tissues, including bone (3) . In endochondral bone formation, the avascular cartilage which pre-cedes bone may produce antiangiogenic factor(s) (4) , while the appearance of osteoblasts coincides with blood vessel invasion (5, 6) . Furthermore, surgical vascularized bone grafts are better retained than nonvascularized tissue (7) . A reduction in bone blood flow and microvascular defects in the sinusoidal compartment have been reported in osteoporotic bone as well as in aplastic anemia (8) . Moreover, impairment of vascular supply results in avascular necrosis of bone (9) , indicating the importance of angiogenesis for the development and maintenance of bone tissue.
Prostaglandins (PGs) are produced in bone in response to inflammation, injury, and mechanical stress (10) and have been implicated in the local regulation of bone metabolism ( 11) . Increasing evidence indicates that PGs stimulate bone formation in vivo. Infusion of PGE1 in infants with cyanotic heart disease produces periosteal new bone formation (12) , and systemic and local administration of PGE, or PGE2 increase periosteal and/or trabecular bone formation in dogs and rats (13) (14) (15) . Although it has been shown that PGE2 stimulates proliferation and other osteoblast functions in organ and cell culture (16, 17) , the mechanism of PG stimulation of bone formation in vivo has not yet been clarified.
One ofthe most pronounced effects ofPMs in vivo is on the vascular system. PGE2 and PGE1 can cause vasodilation and stimulate angiogenesis (18) (19) (20) . However, PGs do not stimulate endothelial cell growth, suggesting that the angiogenic effect may be mediated by the paracrine action of angiogenic factors released from other cells.
Vascular endothelial growth factor (VEGF)' is a heparinbinding dimeric glycoprotein that induces endothelial cell proliferation, angiogenesis, and capillary permeability (21) (22) (23) (24) . Cloning of VEGF cDNAs from several sources demonstrated that four different molecular species ofVEGF are generated by alternative splicing of mRNA (VEGF,21, VEGF165, VEGF189, and VEGF206) (25) . VEGF is distinct from other identified endothelial cell mitogens such as fibroblast growth factors, in that VEGF is a secreted protein (25) , an endothelial cell-specific mitogen in vitro, and the only known growth factor with vascular permeability-inducing activity (26) . VEGF mRNA is expressed in a variety of highly vascularized tissues such as pituitary glands, brain, lung, heart, and kidney (27, 28 ) were analyzed by 4-20% gradient SDS-PAGE under reducing conditions and transferred to nitrocellulose membranes (GIBCO BRL). The membranes were blocked in Blotto (5% nonfat dry milk, 2 mM CaCl2, 0.05% Tween 20, 0.01% Antifoam A, 50 mM Tris, pH 8.0) for 1 h at room temperature and subsequently incubated with anti-rat VEGF polyclonal antibody in Blotto at 4VC overnight. The membranes were washed with Blotto for 20 min three times and incubated with anti-rabbit IgG-AP conjugate for 1 h at room temperature. After washing with Blotto, TBST ( 150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.05% Tween 20), TBS ( 150 mM NaCl, 10 mM Tris-HCI, pH 8.0), and AP buffer (100 mM NaCl, 5 mM MgCl2, 100 mM Tris-HCI, pH 9.5) for 10 min each, the membranes were incubated with substrate solution containing 66 Ml nitroblue tetrazolium (Promega Corp.), 33 Ml BCIP (5-bromo-4-chloro-3-indolyl phosphatase) (Promega Corp.), and 10 ml AP buffer.
Results
Induction of VEGF by PGE2 in osteoblastic cells. RCT-3 cells express osteoblastic features, such as alkaline phosphatase, type I collagen, osteopontin, parathyroid hormone, and PGE2-responsive adenylate cyclase (33) . Since POE2 was shown to increase bone formation, we evaluated the effects of PGE2 on VEGF mRNA in these osteoblastic cells. RNA prepared from untreated cultures ofRCT-3 cells contains a single VEGF transcript of -3.8 kb. Treatment of RCT-3 cells with M PGE2 resulted in a rapid and transient increase in the level of VEGF mRNA which peaked at 60 min and declined to basal levels within 3 h (Fig. 1 A) . The increased expression of VEGF mRNA induced by PGE2 was dose dependent as shown in Fig.  1 B ( 10-8_10-6 M). A similar rapid increase in VEGF mRNA levels by PGE2 was also seen in rat calvaria-derived osteoblastenriched cells (Fig. 2 ). PGE2 did not increase the level ofother angiogenic factors such as TGF-#31 or basic fibroblast growth factor mRNA in these cells (data not shown).
To confirm that PGE2 increased the expression of VEGF protein as well as VEGF mRNA, conditioned medium was collected from rat calvaria-derived osteoblast-enriched cells after treatment with 10-6 M PGE2 and was analyzed by immunoblotting using affinity-purified polyclonal antibody against the NH2-terminal peptide of rat VEGF. Conditioned media from control cultures contained immunoreactive polypeptides of 24 and 18 kD (Fig. 3) , similar in size to the murine VEGF (36) . Treatment with 10-6 M PGE2 for 3-6 h increased VEGF protein levels in conditioned media threefold (Fig. 3) . Similar increases in VEGF protein levels by PGE2 were observed in conditioned media of RCT-3 cells (data not shown).
Effects ofprotein synthesis and RNA synthesis inhibitors on
VEGFmRNA. The rapid increase ofVEGF mRNA induced by PGE2 and the subsequent rapid decline in osteoblastic cells ( Fig. 1 A) suggest rapid turnover of VEGF mRNA similar to that ofearly genes, such as c-fos and c-myc, and low stability of VEGF mRNA. To characterize the mechanism for PGE2 upregulation ofVEGF mRNA, we examined the effects ofinhibitors of protein synthesis and RNA polymerase. In RCT-3 cells, the increase in VEGF mRNA after 60 min oftreatment with PGE2
was potentiated by cycloheximide (5 Mg/ml), which alone had (kD) Figure 3 . blast-enriched cells. Fetal rat calvaria-derived osteoblast-enriched cells were cultured in serum-free media for 6 h and were treated with PGE2 for the indicated times. Media were concentrated by a Centricon-10 (Amicon Corp.), and aliquots ( 150 ,g of protein) were examined by immunoblot analysis using affinity-purified polyclonal antibody against NH2-terminal polypeptide of rat VEGF as described in Methods. Molecular markers in kilodaltons are indicated by arrowheads. The figure represents the results from one of three similar experiments.
cells (38, 39) . As shown in Fig. 6 , PGE,, which increases intracellular cAMP levels but does not induce phosphatidyl inositol turnover in osteoblastic cells (38, 39) , was as potent as PGE2 in increasing VEGF mRNA levels, suggesting cAMP mediation.
A .I.
-28S no effect on VEGF mRNA at that time point. Furthermore, at 3 h, when VEGF mRNA declined to basal levels after PGE2 treatment, cycloheximide maintained increased VEGF mRNA levels, suggesting that cycloheximide prevented the degradation of VEGF mRNA (Fig. 4 A) . On the other hand, the effect of PGE2 on VEGF mRNA was abolished completely by the addition ofactinomycin D (2 gg/ml) or DRB (25 ,g/ml) (Fig.   4 B) , suggesting transcriptional regulation ofVEGF expression by PGE2.
To further study the mechanism ofVEGFmRNA upregulation by PGE2, we examined the effect of PGE2 on the stability ofVEGF mRNA. RCT-3 cells, pretreated with TPA ( 150 nM), which was shown to increase steady state levels of VEGF mRNA (37) , were subsequently treated with DRB (25 ,ug/ml) in the presence or absence of PGE2 ( 10-6 M). PGE2 further increased VEGF mRNA pretreated by TPA in the absence of DRB (Fig. 5 A) , but had no effect on the half-life of VEGF mRNA (Fig. 5 B) . These results are consistent with PGE2 stimulation of VEGF mRNA transcription in osteoblastic cells.
Role ofcAMP in PGE2 induction of VEGF mRNA. It has been shown that PGE2 increases intracellular cAMP levels as well as phosphatidyl inositol turnover in cultured osteoblastic antagonist (40) , inhibited the effect of PGE2 on VEGF mRNA (Fig. 7 B) , pointing to possible mediation by intracellular cAMP in PGE2 induction of VEGF mRNA in osteoblastic cells.
Differentiation-related upregulation of VEGF expression by PGE2 in preosteoblastic cells. RCT-1 cells are clonal simian virus 40 immortalized preosteoblastic cells, in which retinoic acid induces differentiation (33) . Pretreatment of these cells with retinoic acid ( 10-6 M) for 7 d strongly potentiated the effect of PGE2 (10-6 M) on VEGF mRNA (Fig. 8 A) . As shown in Fig. 8 (22) , VEGF mRNA was barely detectable by polyadenylated RNA preparation and was not regulated by PGE2 (Fig. 9) . Suppression ofPGE2 upregulation of VEGF mRNA by glucocorticoids. In RCT-3 cells, the increase in VEGF mRNA after 60 min of treatment with PGE2 (1 -6 M) was strongly attenuated by dexamethasone (Dex) (l0-' M), which alone also decreased the levels of VEGF mRNA (Fig. 10 A) . PGE2 upregulation of VEGF mRNA was also suppressed after pretreatment with Dex ( l0-7 M) for periods as short as 1 h, while pretreatment with either 1,25(OH)2D3 ( 10-8 M) or estradiol ( I0-7 M) had no effect on VEGF mRNA (Fig. l0 B) . Pretreatment with Dex also suppressed the increase in VEGF mRNA caused by TPA ( 150 nM) (Fig. 10 C) , suggesting that Dex may modulate directly the level of VEGF mRNA.
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Retinoic Acid (1 0-6M) Pretreatment Expression of VEGF mRNA in adult rat tibia. To examine if VEGF is expressed in bone tissue in vivo, polyadenylated RNA was isolated from 4-5-wk-old rat tibia and analyzed by RNA blotting with the VEGF cDNA probe. A single transcript of 3.8 kb was observed in this RNA preparation, indicating VEGF expression in bone tissue (Fig. 11 ).
Discussion
Formation of new blood vessels under tight, spatial, and temporal control is required for the development and repair of all that acts exclusively on endothelial cells (27) . The specific association of VEGF mRNA and the expression of one ofits receptors,flk-J, with vascular endothelial cells at all stages of mouse development suggest that VEGF plays a physiological role in development (27-30, 41, 42) . Moreover, vascularization of the cartilage anlage is an early event in bone development, and VEGF as well asflk-J mRNA expression is prominent in the intersegmental regions of the vertebrae in rat or mouse embryos (41, 42) .
In this study, we show that VEGF mRNA is expressed in rat calvaria-derived osteoblast-enriched cells, in clonal osteoblastic cells, and in bone tissue, and that PGE2, which is a potent stimulator of osteogenesis in vivo, causes rapid induction of VEGF mRNA and VEGF production in osteoblastic cells. The rapid short-lived induction of VEGF mRNA in osteoblastic cells by PGE2 is consistent with a tight regulation ofangiogenesis both in time and space. VEGF mRNA was barely detectable and was not regulated by PGE2 in HUVE cells, which proliferate in response to VEGF, suggesting that VEGF may act as a paracrine factor rather than an autocrine factor.
PGs are among the most potent inducers ofbone formation in vivo. Systemically and locally administered PGE2 and PGE1 were shown to stimulate bone formation in rat, dog, and humans (12) (13) (14) (15) . PGs stimulate proliferation of osteoblastic cells (38, 39) and increase steady state levels of IGF-I mRNA (43) and the binding of IGF-I to its receptor (44) and its mRNA level (45) in vitro. However, the lack of osteogenic activity by PGF2,t (Balena, R., S. Harada, S. B. Rodan, and G. A. Rodan, manuscript in preparation), a potent mitogen for osteoblasts in vitro (38, 39, 45) , and the lack ofmitogenic activity ofPGEI in vitro (38, 39, 45) suggest that in vitro mitogenic activity does not explain the in vivo osteogenic effects (45) . Furthermore, the lack of strong osteogenic activity of IGF-I in vivo and the late expression ofIGF-I mRNA in ablation-induced osteogenesis (46) suggest that IGF-I mediation can not fully explain the osteogenic effect of PGE. Recent observations in mice carrying null mutations of igf-J and igflr showed delayed but grossly normal bone development (47) . Thus, IGF-I may play a role in the maintenance of bone rather than de novo bone induction. Since PGE2 and PGEI but not PGF2, (data not shown) strongly stimulate the expression ofVEGF and since angiogenesis is associated with the early phase ofbone formation (5, 6) , the induction of VEGF may play a role in PGE stimulation of bone formation in vivo. However, further studies are required to evaluate the role of VEGF in osteogenesis in vivo.
Regarding the mechanism for PG induction of VEGF, PGs can increase intracellular cAMP levels and phosphatidyl inositol turnover in osteoblastic cells (38, 39) . Although stimulation of both protein kinase C and protein kinase A were shown to increase VEGF mRNA expression in other cell types (36, 37) , the suppression of the PGE2 effect by H7 and by the cAMP antagonist, Rp-cAMP, but not by staurosporine implicates mediation by cAMP. However, the involvement of other second messengers cannot be excluded, since other stimulators of cAMP accumulation, forskolin, dibutyryl cAMP, and PTH did not increase VEGF mRNA levels as much as PGE, and PGE2. Recently, cDNAs for three different PGE2 receptors were identified (48) (49) (50) . Examination of the expressions and functions of these PGE2 receptors in osteoblasts may further elucidate the mechanisms for PGE2 upregulation of VEGF as well as for PGE2 induction of osteogenesis.
Tissue development requires the formation of new blood vessels to support proper function. Stimulation of VEGF expression by PGE2 in the preosteoblastic RCT-1 cells was strongly potentiated by pretreatment with retinoic acid, which induces differentiation in these cells (33) . Osteoblasts originate from pluripotent mesenchymal progenitor stem cells, which also give rise to muscle cells, adipocytes, and other cell types (51, 52) . It has been shown that VEGF mRNA expression is also upregulated during the differentiation of adipocytes and myoblasts (36) . Our observations, in addition to the previous findings, suggest that VEGF expression is linked to the differentiation ofthe cells originating from mesenchymal stem cells. Interestingly, pretreatment of RCT-1 cells with retinoic acid also potentiated PGE2 induction of IGF-I mRNA (data not shown), which was shown to be associated with newly developed bone (53) . The osteogenic effects of PGE2 may thus involve the production of a series of autocrine and paracrine peptide factors.
A role for VEGF in bone metabolism is further supported by the suppression of PGE2-induced VEGF mRNA by glucocorticoids. Long-term glucocorticoid treatment inhibits bone formation and causes bone loss (54) . Furthermore, glucocorticoid treatment can induce avascular necrosis of bone (55) . Suppression of VEGF expression by glucocorticoid could thus be involved in the pathogenesis ofglucocorticoid-induced bone disorders.
In summary, we documented, for the first time, the expression of VEGF in osteoblasts and in bone tissue. Stimulation of VEGF expression by PGs and its suppression by glucocorticoid which, respectively, stimulate and suppress bone formation strongly implicate the involvement of VEGF in the physiology and pathological metabolism of bone tissue.
